anavex.com (AVXL): Enterprise Value to EBITDA Ratio
The prospects for Anavex Life Sciences (AVXL) are based on the success of blarcamesine trials and the anticipation of regulatory approvals. The company's EV/EBITDA ratio clearly demonstrates the dynamics of these expectations, with the current value of the metric standing at 0.00. Patent protection for SIGMAR1 activation provides stability, while the development of small molecules to combat Parkinson's disease ensures sustainable long-term demand for the therapy.
Comprehensive metric breakdowns and analytics for anavex.com (AVXL)
- current price and projected stock value:
- stock exchange capitalization data:
- business book valuation details:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Anavex Life Sciences|AVXL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Anavex Life Sciences Corp.|AVXL - Company Debts|Debts to Book Capitalization Anavex Life Sciences Corp|AVXL - Long-Term Debt Volume|Company Short-Term Debts Anavex Life Sciences|Quick Ratio anavex.com
- financial results and valuation multiples details:
AVXL - Company Net Income|Future Profit Anavex Life Sciences|AVXL - Company Value to Net Income|Future Price to Earnings Anavex Life Sciences|AVXL - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Anavex Life Sciences Corp|AVXL - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Anavex Life Sciences|AVXL - Net earnings per share for the last four quarters|Quarterly EPS earnings growth anavex.com|AVXL - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Anavex Life Sciences
- revenue and sales details:
Summary company analytics:Anavex Corp AVXL
To isolate the fundamental stability of Anavex Life Sciences (AVXL) from market noise, the EV/EBITDA metric is utilized, comparing the total enterprise value with operating profit before depreciation and amortization. By analyzing the EV/EBITDA chart against historical data, an investor assesses the company's ability to service its obligations, which is critical for the biopharma sector given its high patent scalability and low production costs upon entering the global market.
Analysis of competing companies
EV/EBITDA Multiple BIIB (Biogen Corp)|EV/EBITDA Multiple Neurocrine Corp NBIX|RGC: Enterprise Value to EBITDA Ratio|AXSM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACAD: EV/EBITDA Multiple|Company Value to EBITDA Xenon Pharmaceuticals Inc. (XENE)|Enterprise Value to EBITDA Ratio VKTX|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus Corp)|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|Biohaven Ltd - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Amylyx - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Trevi Corp TRVI|PRAX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio CBLL (ceribell.com)|PRTA (Prothena Corporation plc) - EV/EBITDA Multiple|Company Value to EBITDA Alector Therapeutics ALEC|Enterprise Value to EBITDA Ratio ANNX (Annexon Inc.)|OMER (omeros.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurogene Inc. NGNE|Total Company Value to Operating Income Before Depreciation Ratio acimmune.com (ACIU)|Voyager Therapeutics, Inc. - EV/EBITDA Multiple|Neumora (NMRA) - Enterprise Value to EBITDA Ratio|SCLX: EV/EBITDA Multiple|TVGN - Total Company Value to Operating Income Before Depreciation Ratio|ACOG (Alpha Cognition Inc) - EV/EBITDA Multiple|Company Value to EBITDA cogrx.com CGTX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inhibikase Therapeutics, Inc. (IKT)|Cassava Sciences Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ASRT (Assertio)|COYA - Enterprise Value to EBITDA Ratio|VistaGen Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Ovid Therapeutics Inc.|Acumen Pharmaceuticals, Inc. (ABOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRVO - Total Company Value to Operating Income Before Depreciation Ratio|ATHE (Alterity Therapeutics Ltd.) - EV/EBITDA Multiple|EV/EBITDA Multiple Clene Nanomedicine|Enterprise Value to EBITDA Ratio PEPG (PepGen Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization JUNS (jupiterneurosciences.com)|Relmada Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|ANVS: Enterprise Value to Operating Income Before Depreciation|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AIFF: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|anewmeds.com (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation NRSN|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA MetaVia, Inc. MTVA|Enterprise Value to EBITDA Ratio NRXS (NeurAxis, Inc)|EV/EBITDA Multiple heliusmedical.com (HSDT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|Business Value to Operating Income Before Depreciation NEUP|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Athira Pharma Inc|ADXN: EV/EBITDA Multiple|Alzamend Neuro (ALZN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Enterprise Value to Operating Income Before Depreciation PTIX (Protagenic)|EV/EBITDA Multiple KTTA|EV/EBITDA Multiple cortigent.com (CRGT)|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|BrainStorm Cell Therapeutics Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA chromocell.com|ELYM (eliemtx.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to EBITDA Ratio LBPH|MRNS: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NRBO (neurobopharma.com)|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Synaptogenix Inc. (SNPX)|Trevena, Inc - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA cerevel.com (CERE)
